Effectiveness of medical supportive team for outpatients treated with sorafenib: A retrospective study

Journal of Pharmaceutical Health Care and Sciences

Volumn 1, Issue 1, 2015, Pages

  Kajizono, Makoto ^a   Aoyagi, Megumu ^a   Kitamura, Yoshihisa ^a   Sendo, Toshiaki ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adverse drug reactions; Hand foot skin reactions; Hepatocellular carcinoma; Medical supportive team; Outpatient; Renal cell carcinoma; Sorafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; SORAFENIB;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HAND FOOT SYNDROME; HEALTH CARE PERSONNEL; HOARSENESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MEDICAL SUPPORTIVE TEAM; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT CARE; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 85011897622     PISSN: None     EISSN: 20550294     Source Type: Journal    
DOI: 10.1186/s40780-014-0005-0     Document Type: Article

References (20)

1. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
4. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006, 5:835-844.
5. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7:3129-3140.
6. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
7. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, Wechsler J, Lhomme C, Escudier B, Boige V, Armand JP, Le Chevalier T: Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005, 6:491-500.
8. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:2505-2512.
9. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008, 13:1001-1011.
10. Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011, 47:2117-2127.
11. Walko CM, Grande C: Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective. Semin Oncol 2014, 41(Suppl 2):S17-S28.
12. Aimono Y, Nemoto M, Sato W, Saito Y, Aoyama Y, Joko F, Maruyama T, Kamoshida T: [Examination of the usefulness of the pharmacists' outpatient clinic for treatment with oral molecule-targeting drugs]. Gan to Kagaku Ryoho 2013, 40:901-905.
13. Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, Gutzmer R: The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 2010, 8:652-661.
14. Porta C, Paglino C, Imarisio I, Bonomi L: Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007, 7:127-134.
15. Kawashima A, Takayama H, Arai Y, Tanigawa G, Nin M, Kajikawa J, Imazu T, Kinoshita T, Yasunaga Y, Inoue H, Nishimura K, Takada S, Nishimura K, Tsujimura A, Nonomura N: One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients. Eur J Cancer 2011, 47:1521-1526.
16. Tanigawa G, Kawashima A, Yamaguchi S, Nishimura K, Miyoshi S, Kajikawa J, Meguro N, Yosioka T, Oka T, Hara T, Takayama H, Nonomura N: Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice. Jpn J Clin Oncol 2011, 41:1265-1270.
17. Okuwaki Y, Nakazawa T, Hidaka H, Shibuya A, Koizumi W: Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. J Med Case Rep 2012, 6:38.
18. Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T: Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012, 4:423-429.
19. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol 2010, 5:59-63.
20. Ueda T, Imamura Y, Komaru A, Fukasawa S, Sazuka T, Suyama T, Naya Y, Nihei N, Ichikawa T, Maruoka M: Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients. Int J Urol 2010, 17:811-815.